Shares of Medtronic (NYSE: MDT) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices ...

Brett A. Wall, Executive Vice President and President of Neuroscience at Medtronic plc (NYSE:MDT), a $118 billion market cap ...

chief medical officer of the Diabetes Group at Medtronic. "The data demonstrating the benefits of this system are compelling and I'm confident it will simplify diabetes care for both patients and ...

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Medtronic executives outlined four categories where the company expects the highest growth from new products in the near term: cardiac ablation, renal denervation, neuromodulation and automated ...

Peralta will be responsible for leading worldwide manufacturing operations, including driving alignment of operations with ...

Medtronic has several products, such as AiBLE (spinal implants) and Percept (brain modulation), that have been getting adopted Its diabetes segment, while the smallest business (about 8% of ...

Diabetes mellitus is a metabolic disease that causes high blood sugar. Your body either doesn’t make enough insulin or can’t effectively use the insulin it makes. The hormone insulin moves ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Medtronic (MDT – Research Report). The company’s ...